Vivesto AB (VIVE) - Total Liabilities
Based on the latest financial reports, Vivesto AB (VIVE) has total liabilities worth Skr16.44 Million SEK (≈ $1.77 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how efficiently does Vivesto AB generate cash to assess how effectively this company generates cash.
Vivesto AB - Total Liabilities Trend (2004–2024)
This chart illustrates how Vivesto AB's total liabilities have evolved over time, based on quarterly financial data. Check VIVE cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Vivesto AB Competitors by Total Liabilities
The table below lists competitors of Vivesto AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
PMPG Polskie Media S.A.
WAR:PGM
|
Poland | zł8.43 Million |
|
Hydrofarm Holdings Group Inc
NASDAQ:HYFM
|
USA | $191.40 Million |
|
Linkage Global Inc Ordinary Shares
NASDAQ:LGCB
|
USA | $33.96K |
|
Bang Overseas Limited
NSE:BANG
|
India | Rs1.03 Billion |
|
Aptorum Group Ltd Class A
NASDAQ:APM
|
USA | $4.90 Million |
|
JPMorgan Indian Inv Trust
LSE:JII
|
UK | GBX24.00 Million |
|
Masivo Silver Corp
V:MASS
|
Canada | CA$479.21K |
|
Destiny Media Technologies Inc
V:DSY
|
Canada | CA$496.86K |
Liability Composition Analysis (2004–2024)
This chart breaks down Vivesto AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Vivesto AB (VIVE) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.38 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Vivesto AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Vivesto AB (2004–2024)
The table below shows the annual total liabilities of Vivesto AB from 2004 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr14.55 Million ≈ $1.57 Million |
-36.38% |
| 2023-12-31 | Skr22.87 Million ≈ $2.46 Million |
-24.89% |
| 2022-12-31 | Skr30.45 Million ≈ $3.28 Million |
-31.71% |
| 2021-12-31 | Skr44.59 Million ≈ $4.80 Million |
-74.78% |
| 2020-12-31 | Skr176.80 Million ≈ $19.03 Million |
-4.92% |
| 2019-12-31 | Skr185.96 Million ≈ $20.01 Million |
-16.36% |
| 2018-12-31 | Skr222.33 Million ≈ $23.93 Million |
-0.32% |
| 2017-12-31 | Skr223.04 Million ≈ $24.00 Million |
+0.83% |
| 2016-12-31 | Skr221.21 Million ≈ $23.81 Million |
+16.72% |
| 2015-12-31 | Skr189.53 Million ≈ $20.40 Million |
+36.49% |
| 2014-12-31 | Skr138.86 Million ≈ $14.94 Million |
-25.54% |
| 2013-12-31 | Skr186.48 Million ≈ $20.07 Million |
+47.97% |
| 2012-12-31 | Skr126.03 Million ≈ $13.56 Million |
+65.10% |
| 2011-12-31 | Skr76.33 Million ≈ $8.21 Million |
+191.93% |
| 2010-12-31 | Skr26.15 Million ≈ $2.81 Million |
-30.91% |
| 2009-12-31 | Skr37.85 Million ≈ $4.07 Million |
+5.45% |
| 2008-12-31 | Skr35.89 Million ≈ $3.86 Million |
+57.01% |
| 2007-12-31 | Skr22.86 Million ≈ $2.46 Million |
+117.80% |
| 2006-12-31 | Skr10.50 Million ≈ $1.13 Million |
+118.84% |
| 2005-12-31 | Skr4.80 Million ≈ $516.16K |
+2.90% |
| 2004-12-31 | Skr4.66 Million ≈ $501.61K |
-- |
About Vivesto AB
Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also offers Apealea, an injectable formulation of paclitaxel for the treatment of various cancers. In addition, it develops Cantrixi… Read more